Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Cost of Revenue (2021 - 2025)

Tg Therapeutics (TGTX) has 5 years of Cost of Revenue data on record, last reported at $38.1 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 147.69% year-over-year to $38.1 million; the TTM value through Dec 2025 reached $100.7 million, up 161.69%, while the annual FY2025 figure was $100.7 million, 161.69% up from the prior year.
  • Cost of Revenue reached $38.1 million in Q4 2025 per TGTX's latest filing, up from $28.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $38.1 million in Q4 2025 and bottomed at $3000.0 in Q4 2022.
  • Average Cost of Revenue over 5 years is $11.0 million, with a median of $8.1 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: surged 261700.0% in 2023, then surged 96.07% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $139000.0 in 2021, then crashed by 97.84% to $3000.0 in 2022, then soared by 261700.0% to $7.9 million in 2023, then soared by 96.07% to $15.4 million in 2024, then soared by 147.69% to $38.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $38.1 million in Q4 2025, $28.1 million in Q3 2025, and $18.9 million in Q2 2025.